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Abstract
Background: Lifestyle factors have been implicated in ischaemic heart disease (IHD) development however a
limited number of longitudinal studies report results stratified by cardio-protective medication use.
Purpose: This study investigated the influence of self-reported lifestyle factors on hospitalisation for IHD, stratified by
blood pressure and/or lipid-lowering therapy.
Methods: A population-based cohort of 14,890 participants aged 45+ years and IHD-free was identified from the
Western Australian Health and wellbeing Surveillance System (2004 to 2010 inclusive), and linked with hospital
administrative data. Adjusted hazard ratios for future IHD-hospitalisation were estimated using Cox regression.
Results: Current smokers remained at higher risk for IHD-hospitalisation (adjusted HR=1.57; 95% CI: 1.22-2.03)
after adjustment for medication use, as did those considered overweight (BMI=25-29 kg/m2; adjusted HR=1.28; 95%
CI: 1.04-1.57) or obese (BMI of ≥30kg/m2; adjusted HR=1.31; 95% CI: 1.03-1.66). Weekly leisure-time physical
activity (LTPA) of 150 minutes or more and daily intake of 3 or more fruit/vegetable servings reduced risk by 21%
(95% CI: 0.64-0.97) and 26% (95% CI: 0.58-0.96) respectively. Benefits of LTPA appeared greatest in those on blood
pressure lowering medication (adjusted HR=0.50; 95% CI: 0.31-0.82 [for LTPA<150 mins], adjusted HR=0.64; 95%
CI: 0.42-0.96 [for LTPA>=150 mins]). IHD risk in smokers was most pronounced in those taking neither medication
(adjusted HR=2.00; 95% CI: 1.41-2.83).
Conclusion: This study confirms the contribution of previously reported lifestyle factors towards IHD hospitalisation,
even after adjustment for antihypertensive and lipid-lowering medication use. Medication stratified results suggest
that IHD risks related to LTPA and smoking may differ according to medication use.
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Introduction
Identification and management of lifestyle risk factors for
cardiovascular disease (CVD), together with advances in
preventive pharmacotherapy have reduced CVD-related
mortality in most high-income countries [1], including Australia
[2]. Despite this promising trend, death from CVD (of which
ischaemic heart disease [IHD] is the most common form)
mostly leads national statistics in these jurisdictions [1]. IHD
remains the leading underlying cause of death in Western
Australia, with an age-standardised death rate of 79.5 deaths
per 100,000 people [3]. This is almost twice the rate of the 2nd
highest cause of death (malignant neoplasms of the digestive
organs) which has a standardised death rate of 44 per 100,000
[3].
A number of biomedical and behavioural risk factors have
been identified for the development of CVD. These risk factors
include smoking, diabetes mellitus (DM), insufficient physical
activity, hypertension, high cholesterol, overweight and obesity,
and an unhealthy diet [4,5]. Current guidelines for people with
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hypertension and/or dyslipidaemia include pharmacologic and
lifestyle interventions for their control and management [6,7].
The effectiveness of such medications in preventing premature
IHD is well documented [7]; however an individual’s response
to pharmacotherapy is variable and influenced by such factors
as genetics, gender, age, weight, smoking status and physical
activity levels [8]. We investigated the risks associated with
various lifestyle factors, not only in overall terms but also within
groups of people on specific blood pressure and lipid-lowering
medications.
Methods
Ethics Statement
The study was approved by the Human Research Ethics
Committees of Edith Cowan University and the Western
Australian Department of Health, and has therefore been
performed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki and its later amendments.
This population-based cohort study utilised self-reported
lifestyle survey information (from the Health and Wellbeing
Surveillance System [HWSS]) individually linked with hospital
admission data (both held by the Western Australian
Department of Health). The HWSS is a comprehensive monthly
survey commissioned by the Health Department to provide
information on a wide range of issues pertaining to the Western
Australian population’s physical and mental well-being. It
utilises computer-assisted telephone interviewing to assess
approximately 6,000 Western Australians each year who are
selected from the WA White Pages® telephone directory using
a stratified random process with over-sampling representative
to the population in rural and remote areas. Each year since its
inception, more than 75% of those contacted completed the
survey [9] and a majority (77% in 2010) of participants provided
their name, address and date of birth for the purpose of linkage
with administrative health data. Only those HWSS participants
who provided consent for their information to be used in this
manner were linked to other registries for this study. The
probabilistic matching procedures used to link individuals are
based on full name and address, phonetic compression
algorithms and other identifiers, and have been estimated to be
99.89% accurate [10]. This linkage allowed identification of
incident IHD hospitalisations following an initial survey date and
provided information on medication use, behavioural factors
and demographics at the time of survey.
Study Population
Between 1 January 2004 and 31 December 2010, some
40,445 surveys for which consent was provided for data
linkage, were completed as part of the HWSS. Where
participants had been surveyed more than once (1,671 people)
during the study period, their first survey was included for
analysis. Upon further restriction to those eligible for a
subsidised health check-up with their doctor, i.e. aged 45+
years and without prior IHD-hospitalisation, a final study cohort
of 14,890 remained.
Study Variables
Exposures of interest included smoking status (never more
than 100 cigarettes, ex-smoker, current-smoker), leisure-time
physical activity (LTPA) in past week (none, <150min,
≥150min), fruit and/or vegetable intake daily (<3, ≥3 pieces),
and body mass index (BMI; <25, 25-29, 30+ kg/m2). These
exposures were also stratified by self-reported current use (at
time of survey) of medications for high blood pressure or
elevated total cholesterol. Participants were grouped into 4
categories; no current use of antihypertensive or lipid-lowering
medications, antihypertensive medications only, lipid-lowering
medications only, both antihypertensive and lipid-lowering
medications. The primary outcome was hospitalisation for IHD
according to the principal diagnosis (International Classification
of Diseases [ICD] – version 9 [ICD-9] 410-414 or ICD-10 I20-
I25) post survey date. The study population was restricted to
those having no previous IHD-related hospitalisation (in any of
the 22 administrative diagnostic categories) within 5 years of
the survey date.
LTPA included minutes of walking (in at least 10 min blocks),
moderate and vigorous activity, where minutes of vigorous
activity were multiplied by two (as described in the Australian
physical activity guidelines [11]). For those aged 65+, no
weighting was applied for vigorous activity in order to improve
comparability between years due to the question not being
asked for that age group prior to 2008. Few respondents aged
65+ reported being vigorously active from 2008 onwards.
Minutes of activity were grouped as meeting public health
guidelines for sufficient levels of LTPA (0, <150 minutes, ≥150
minutes). For those whose total LTPA per week exceeded
1,680 minutes, their summed value was re-coded to 1,680
minutes for analysis (as recommended by the Australian
Institute of Health and Welfare [11]).
Categorisation of self-reported daily fruit and vegetable
intake was based on evidence suggestive of a protective effect
of 3 or more fruit/vegetables daily on fatal-IHD risk [12]. BMI
categories, also self-reported, were classified as underweight/
normal (<25 kg/m2), overweight (25-29 kg/m2) or obese (30+
kg/m2) [13]. Sedentary behaviour was categorised according to
the mean and quartiles for time in this state. These sedentary
categories (<10, 10-14, 15-21, 22+ hours per week) were
based on participant recall of the average number of hours per
week spent watching TV, videos, or using a computer for any
reason. Prior to 2006, these responses for participants younger
than 65 years did not exclude work time whereas from 2006
work time sedentary behaviour was excluded.
In order to determine participants’ medication usage at time
of survey, participants were asked if they took any medication
for blood pressure, and separately asked if they took
medication for high cholesterol. Disaggregation to class of anti-
hypertensive or lipid-lowering agent was not possible, nor was
ascertainment of dosage or adherence.
Additional confounding factors adjusted for in the analyses
were age at survey (45-59, 60-70, 70+ years), year of survey,
gender, diagnosis of DM in any hospitalisation diagnostic
category within 5 years prior to the survey date, and Charlson
comorbidity index score (based on a modified Dartmouth-
Manitoba algorithm [14]) within five years prior to the survey
Lifestyle, Medications and Ischaemic Heart Disease
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date. Charlson comorbidity index and prior DM were generated
using ICD-9 and ICD-10AM codes contained within the
diagnostic hospital records.
Statistical Analyses
Person-time was calculated from the date of survey until the
admission date for a principal IHD-hospitalisation, death, or
until end of follow-up (31 Dec 2010), whichever occurred first.
Cox proportional hazards regression models were used to
estimate hazard ratios (HR) with 95% confidence intervals
(CIs) for future IHD-hospitalisation. The final adjusted model
included age, sex, smoking status, Charlson comorbidity index,
LTPA, sedentary behaviour, BMI, daily fruit and vegetable
intake, survey year, and known DM. Socioeconomic index for
areas (SEIFA) and region (metro or regional residence) were
not included in the adjusted model as they were not
significantly associated with the outcome in crude Cox models.
The proportional hazards assumption that the ratio of
mortality rates according to the exposure variable remained
constant for the adjusted models was tested by inclusion of an
interaction term with ln(1 + survival time) in the model. This
identified one violation of the proportional hazards, namely
BMI. We further tested this by estimating HRs and their
confidence intervals separately by number of years of follow-
up. A 24-27% higher HR estimate (for 25-29 and 30+ kg/m2
respectively) was observed in the 1st year of follow-up,
compared to the 2nd follow-up period (2 years), however
overlapping confidence intervals suggest the differences were
not significant. Subsequent HR estimates for longer follow-up
periods differed by about 3% to their previous year’s HR
estimate and similarly had overlapping confidence interval
compared with the 1st year confidence intervals. We therefore
presented the HR estimates for the entire period rather than
stratified by year. To test whether or not the HR estimates for
other risk factors might differ as a result of any possible
violation in propotional hazards by BMI, an adjusted Cox
regression model stratified by BMI (BMI was placed in a strata
statement) was performed. Estimates did not vary by more
than 0.05 following stratification of BMI.
For all analyses, a two sided P<0.05 was considered
statistically significant. The statistical software SAS 9.3 was
used to perform all analyses.
Results
Baseline Characteristics
Females made up 59% (n=8,776) of the final study cohort
(Table 1) which ranged in age from 45 to 97 years. Fifty eight
percent of those surveyed reported no current use of
antihypertensive or lipid-lowering medications, just over half of
those being aged between 45 and 60 years. Self-reported
current use of antihypertensive medications (with or without
lipid-lowering medications) increased with age; however the
use of ‘lipid-lowering medications only’ showed relative stability
over all age groups. This latter exposure category also
possessed a slightly higher proportion of males (45%)
compared with the other three medication categories. Prior
hospitalisation for DM was more prevalent in those reporting
use of either medication (compared to those reporting none),
and DM was most prevalent in the combined medication group
where 16% of participants had a DM-hospitalisation within 5
years prior to the survey date. Sufficient LTPA was more
common in people who did not take medications, whereas
sedentary behaviour, DM and high BMI were more common in
people who took medications. Being a current smoker was
more common in people who were not on any medications,
while being a former smoker and eating more fruit and/or
vegetables was more common for people who were currently
taking medications.
The mean number of person-years of follow-up ranged from
2.8 to 3.2 years between exposure groups, with a maximum of
almost seven years for each of the four exposure categories.
The crude IHD-hospitalisation rate ranged from 932 per
100,000 person-years in the ‘no medication’ category, to 2,102
IHD-hospitalisations per 100,000 person-years in the combined
medication group.
Future IHD-hospitalisation, lifestyle factors and current
medication use
After adjustment for current medication use, all a priori
selected risk factors aside from sedentary behaviour
demonstrated significant increased or decreased risk for future
IHD-hospitalisation (Table 2), regardless of medication use.
Weekly LTPA of 150 minutes or more was associated with a
21% (adjusted HR=0.79; 95% CI: 0.64-0.97) decreased risk,
and 3 or more daily servings of fruit/vegetables translated to a
26% (adjusted HR=0.74; 95% CI: 0.58-0.96) decreased risk for
IHD-hospitalisation. Conversely, overweight (BMI=25-29kg/m2)
or obesity (BMI of ≥30kg/m2) afforded an increased risk of 28%
(adjusted HR=1.28; 95% CI: 1.04-1.57) and 31% (adjusted
HR=1.31; 95% CI: 1.03-1.66) respectively, and current smoking
provided a corresponding 57% (adjusted HR=1.57; 95% CI:
1.22-2.03) increased risk for future IHD-hospitalisation.
Addition of interaction terms to the Cox regression model
revealed no significant interaction effects between the
aforementioned risk factors and medication use in future IHD-
hospitalisation.
When adjusted hazard ratios were estimated for risk factors
within sub-groups of medication users (none, antihypertensive
medications only, lipid-lowering medications only, concurrent
antihypertensive and lipid-lowering medications) the beneficial
effects of LTPA were only observed in those on
antihypertensive medications only. However within this
antihypertensive medication sub-group, significant protective
effects of 50% (adjusted HR=0.50; 95% CI: 0.31-0.82) and
36% (adjusted HR=0.64; 95% CI: 0.42-0.96) were observed for
<150 minutes and ≥150 minutes respectively. Within the ‘no
medication’ sub-group, current smoking doubled the risk for
IHD-hospitalisation (adjusted HR=2.00; 95% CI: 1.41-2.83) and
a BMI of 25-29kg/m2 was associated with a 39% (adjusted
HR=1.39; 95% CI: 1.05-1.84) increased risk, compared to
those with a BMI of less than 25kg/m2. Neither smoking nor
BMI demonstrated any significant increased risks within other
sub-groups of medication use, although in some cases this is
likely due a lack of sufficient power within the medication sub-
groups.
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Table 1. Study population characteristics by exposure
category: Persons aged 45+ years with no prior^ IHD,
2004-2010.
 
No
medications
(n=8640)
Hypertension
medications
(n=3081)
Lipid-
lowering
medications
(n=1336)
Both
medications
(n=1833)
 n (%) n (%) n (%) n (%)
Male 3551 (41.1) 1224 (39.7) 605 (45.3) 734 (40.0)
Age at Survey
(years)     
45-59 4639 (53.7) 811 (26.3) 439 (32.9) 355 (19.4)
60-70 2141 (24.8) 963 (32.3) 468 (35.0) 624 (34.0)
70+ 1860 (21.5) 1307 (42.4) 429 (32.1) 854 (46.6)
Leisure-Time
Physical Activity     
None 1913 (22.1) 849 (27.6) 321 (24.0) 556 (30.3)
< 150min (inc
walking) 2243 (26.0) 887 (28.8) 363 (27.2) 543 (29.6)
≥150min (inc
walking) 4484 (51.9) 1345 (43.6) 652 (48.8) 734 (40.0)
Weekly Sedentary
Activity (sitting)     
<10hr 2103 (24.3) 539 (17.5) 249 (18.6) 280 (15.3)
10-14hr 2433 (28.2) 801 (26.0) 323 (24.2) 423 (23.1)
15-21 2240 (25.9) 849 (27.6) 361 (27.0) 505 (27.6)
22+ 1864 (21.6) 892 (29.0) 403 (30.2) 625 (34.1)
Smoking Status     
Never 4027 (46.6) 1563 (50.7) 612 (45.8) 875 (47.7)
Ex-smoker 3274 (37.9) 1209 (39.2) 552 (41.3) 776 (42.3)
Current 1339 (15.5) 309 (10.0) 172 (12.9) 182 (9.9)
3 or more fruit or
veg daily (yes)* 7714 (89.3) 2810 (91.2) 1225 (91.7) 1647 (89.8)
BMI (kg/m2)**     
< 25 3594 (41.6) 883 (28.7) 441 (33.0) 453 (24.7)
25 - 29 3077 (35.6) 1078 (35.0) 534 (40.0) 724 (39.5)
30+ 1545 (17.9) 955 (31.0) 298 (22.3) 586 (32.0)
Previous Diabetes
Mellitus (yes)^ 252 (2.9) 242 (7.8) 112 (8.4) 298 (16.3)
Person-Years of
follow up (mean) 3.2 3.0 2.9 2.8
Person-Years of
follow up (total) 27,353.8 9,303.6 3,881.6 5,091.1
IHD-
hospitalisations
(n)~
255 (3.0) 132 (4.3) 62 (4.6) 107 (5.8)
Crude IHD-
hospitalisation
rate (per 100,000
PY)
932.2 1418.8 1597.3 2101.7
* Missing values recoded to zero for 65 missing responses to fruit and/or
vegetables, and 163 missing responses for mins of leisure-time physical activity.
** Excluded missing values for BMI (n=722).
^ Separation date within 5 years prior HWSS date.
~ Principal diagnosis of IHD at admission.
doi: 10.1371/journal.pone.0077833.t001
Table 2. Hazard Ratios for future IHD-hospitalisation by
self-reported medication use and lifestyle risk factors.
 Hazard Ratios (95% CIs) #
 
No
medications
Hypertension
medications
Lipid-
lowering
medications
Both
medications Total
Total (n)* 8216 2916 1273 1763 14168
Event (n)* 251 126 61 100 538
Weekly
Leisure-
Time
Physical
Activity
     
None Ref Ref Ref Ref Ref
< 150min 0.93(0.66-1.30)
0.50
(0.31-0.82)
1.02
(0.50-2.04)
0.77
(0.46-1.29)
0.80
(0.64-1.00)
≥150min 0.84(0.62-1.14)
0.64
(0.42-0.96)
0.81
(0.42-1.59)
0.86
(0.54-1.39)
0.79
(0.64-0.97)
BMI
(kg/m2)      
< 25 Ref Ref Ref Ref Ref
25 - 29 1.39(1.05-1.84)
1.09
(0.70-1.71)
0.80
(0.44-1.48)
1.67
(0.94-2.94)
1.28
(1.04-1.57)
30+ 1.23(0.85-1.77)
1.19
(0.74-1.91)
1.54
(0.78-3.08)
1.50
(0.82-2.76)
1.31
(1.03-1.66)
Smoking
Status      
Never Ref Ref Ref Ref Ref
Ex-smoker 1.14(0.85-1.53)
1.14
(0.77-1.70)
0.93
(0.52-1.65)
1.25
(0.80-1.95)
1.12
(0.93-1.36)
Current 2.00(1.41-2.83)
1.48
(0.84-2.62)
1.47
(0.66-3.26)
0.86
(0.40-1.84)
1.57
(1.22-2.03)
Daily Fruit
or
Vegetable
intake
     
<3
servings Ref Ref Ref Ref Ref
≥3
servings
0.76
(0.53-1.09)
0.70
(0.40-1.20)
0.54
(0.25-1.17)
0.89
(0.45-1.75)
0.74
(0.58-0.96)
Weekly
Sedentary
Activity
     
<10hr Ref Ref Ref Ref Ref
10-14hr 0.91(0.63-1.31)
1.15
(0.66-2.01)
0.87
(0.37-2.04)
0.88
(0.47-1.67)
0.95
(0.73-1.23)
15-21 1.10(0.77-1.56)
1.20
(0.69-2.07)
1.18
(0.54-2.59)
0.85
(0.46-1.58)
1.09
(0.83-1.38)
22+ 1.08(0.75-1.56)
0.83
(0.47-1.47)
1.26
(0.58-2.75)
0.94
(0.52-1.71)
1.01
(0.78-1.30)
* Numbers differ to Table 1 due to exclusion of any missing values in the Cox
regression analyses.
# Cox model includes age, sex, smoking status, Charlson index, leisure-time
physical activity, sedentary activity level, body mass index, daily fruit and vegetable
intake, survey year, diabetes hospitalisation (within 5 yrs prior survey date).
doi: 10.1371/journal.pone.0077833.t002
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Discussion
In this population-based cohort study of 14,890 Western
Australians, a significant increased risk (adjusted for commonly
reported risk factors) of future IHD-hospitalisation was
observed for those who currently smoked (57% higher), or
were overweight (28% higher) or obese (31% higher). In
contrast, meeting public health guidelines of 150 minutes of
physical activity and daily intake of 3 or more servings of fruit or
vegetables appeared to decrease risk by 21% and 26%,
respectively.
Medication sub-group analyses suggested that benefits or
risks associated with certain lifestyle factors might be more or
less pronounced, depending upon medication use. The
benefits from not being a current smoker were greatest in
individuals who were not taking antihypertensive and/or lipid-
lowering medications, and benefits of higher levels of physical
activity appeared most pronounced in the antihypertensive
medication group.
Estimates of gain from pharmacological therapies in terms of
CVD risk have ranged from 20% to 30% [15,16]. This is likely
due to differences in medication efficacy associated with age,
sex and genetic characteristics, in addition to a number of
lifestyle factors for IHD which may have causal roles
individually or in combination with others [17]. The increased
risk of smoking on IHD has been published widely [2,18–20].
Overall increased risk (an adjusted odds ratio of 2.87) for
myocardial infarction as a function of number of cigarettes in
current smokers (up to 9 times higher risk in those smoking
>40 cigarettes per day) compared to that of non-smokers has
been reported from the INTERHEART study [5]. Whilst our
57% increased risk was relatively low in comparison, the
broader outcome utilised in our study (IHD) probably explains
the lower risk. Smoking did however confer the greatest
increase in risk for IHD-hospitalisation in our study (after
antihypertensive and lipid-lowering medication use) and
interestingly, results suggested the risk might be attenuated
somewhat by the use of antihypertensive and/or lipid-lowering
medications. Synergistic effects between smoking and
hypertension in CVD incidence have been reported previously
[21]. Normalisation of blood pressure through medication use in
current smokers could therefore explain the drop in risk to non-
significant levels in our study. Interestingly, the benefits of
statin use (for controlling dyslipidaemia) on IHD risk in smokers
have also been evidenced previously including a review of the
landmark statin trials [22]. The authors concluded that (in
relation to IHD primary prevention) “One consistent finding
across both primary prevention statin trials was that the lowest
risk of events in any group was in the nonsmokers on active
treatment. The highest risk of events in any group was in the
smokers on placebo.” [22]. Given these previous findings, it is
perhaps not surprising that the lowest risk for IHD-
hospitalisation in current smokers was clearly held by those
participants on both anti-hypertensive and lipid-lowering
medications and those at highest risk were smokers on neither
medication type.
Obesity has consistently been shown to contribute to risk for
IHD in large, well designed studies [23–25]. In the absence of
waist-to-hip ratio measurements, which may be a more
accurate measure in terms of associated risk for obesity and
IHD [25], BMI continues to be useful as a method of adjustment
for confounding which may itself be causal [26]. Yusuf et al [25]
reported a 44% increased risk (top BMI quintile versus the
bottom quintile) for acute myocardial infarction in a large
(12,461 cases) case-control study. The slightly attenuated risks
observed in our study (up to 31% increased risk for obese
participants) are likely due to the broader outcome measure
used in our study (IHD rather than myocardial infarction). A
recent Danish study [26], which included 11,056 IHD events,
found a 26% increased risk of IHD for every 4 kg/m2 increase in
BMI. This suggests our observed risks for overweight and
obese participants are comparably low, however the Danish
study did not adjust for insufficient physical activity or fruit/
vegetable intake which may have contributed toward the
relatively high observed risk.
The impact of physical activity on IHD incidence and
mortality has been reported previously [4,17,19,27,28]. Among
the range of benefits attributable to physical activity are its
effects on glucose control in individuals with type-2 DM,
reduced waist circumference, improvements in high-density
lipoprotein-cholesterol (HDL-C), reduced total and visceral fat,
and decreased blood pressure [28]. Evidence also suggests
that physical activity may play a role in blood pressure control
independently of, and in combination with, the use of
antihypertensive medications. In a study by Calhoun et al [29],
reductions in systolic and diastolic blood pressure were
achieved following a 16 week aerobic exercise regimen
undertaken by a group of men with severe hypertension who
were receiving up to three antihypertensive agents. Reductions
in diastolic blood pressure remained after 32 weeks of
exercise, even following withdrawal of some antihypertensive
medications [29]. In line with this evidence, our study
suggested a reduction in risk for IHD-hospitalisation could be
attained through increased physical activity even after taking
into account participants’ use of cardio-protective medications.
In fact, the largest benefits of physical activity were observed
within the participant group actually taking blood pressure
lowering medications only.
Sufficient fruit and vegetable intake has been implicated as a
risk factor of both fatal and non-fatal IHD [5,12,30–32]. Our
finding of a 26% reduced risk for IHD in those consuming three
or more daily servings of fruit and/or vegetables, reflects results
from a prospective study of 44,561 men and women in the UK
where vegetarians had a 32% lower risk of IHD than non-
vegetarians [31]. Authors of the UK study suggested much of
the reduced risk might be explained by the effects of a
vegetarian lifestyle on IHD risk factors such as non-HDL
cholesterol levels and systolic blood pressure [31]. In our study,
a protective association with daily fruit/vegetable intake
remained even after adjustment for lipid and blood pressure
lowering medications, and many other IHD risk factors.
The population-based nature of this study means that results
can be generalised to the broader community who have access
to a listed telephone line. Whilst there are areas (particularly
remote to very-remote areas) in Western Australia with limited
or no access to telephones, the proportion of the overall
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population is very low. However it should be noted that this
inaccessible population is likely to contain a higher proportion
of indigenous people than is represented by the study cohort.
Importantly, since data were available for all hospitals within
Western Australia, we are likely to have included the vast
majority of those who develop IHD as very few are treated in
the community [33] and migration from Western Australia is
relatively low, particularly in older age groups [34].
Although primary exposures (medication use) and secondary
lifestyle exposures were self-reported, this is unlikely to lead to
a differential misclassification of the exposures due to the
prospective nature of the study. It is therefore most likely that
any misclassification of exposure would underestimate the
actual risk estimates. Our inability to identify which
antihypertensive or lipid-lowering medication(s) participants are
taking, the dosage, and adherence are limitations of this study.
General Practitioner prescription estimates from the BEACH
report [35] suggest that around 80% of antihypertensive
medications are likely to be ACE inhibitors or angiotensin II
agonists (plain or combination medications). Lipid-lowering
medications will likely include one of the three commonly
prescribed statins (Atorvastatin, Rosuvastatin or Simvastatin).
Adherence to cardiovascular medications in a sample of
Australians has been estimated previously at around 67% [36].
Also, adherence to medication is likely to be associated to a
degree with healthy lifestyle factors overall [37]. It is possible
therefore, that the decreased risk for IHD-hospitalisation
observed in those on antihypertensive medication who have
increased physical activity (in the medication-stratified
analyses) is in part due to greater adherence to medication.
However, the lack of a beneficial effect related to being
physically active in the other medication groups suggests
adherence is not the sole reason for this finding. The
availability of only a single observation time point for exposure
measurement may provide some inaccuracies in terms of
exposure classification since the behaviour of participants may
change over time. This is likely to be more prominent for
participants contributing large amount of person-time than
those with less, due to the likelihood that time-points closer to
the survey date will more accurately reflect the participants’
actual lifestyle factors. Whilst this may increase
misclassification of the exposure, the similarities between
mean person-time contributions for the four medication
exposure groups should lessen any differential bias. It is
reassuring that the patterns illustrate increased risks
associated with smoking and BMI, and decreased risks
associated with physical activity and vegetable/fruit intake on
future IHD hospitalisation. These are both highly plausible and
have been evidenced previously in other studies [1,5,17,38,39].
Misclassification of the outcome is unlikely since diagnoses are
derived from administrative hospital data where diagnoses
have been made by hospital clinicians. The sample size for this
study was relatively large and as such had adequate power to
detect significant effects related to the primary exposure and
the lifestyle factors prior to stratification by medication type.
However, the sample size is limited with respect to the
aforementioned medication-stratified analyses. As such, the
absence of significant findings for some lifestyle factors in
stratified analyses should be interpreted with caution.
In conclusion, our study highlights the contribution of
smoking, overweight and obesity, insufficient physical activity,
and low daily fruit and vegetable intake towards IHD
hospitalisation, even after adjustment for antihypertensive and
lipid-lowering medication use, in the Western Australian
population. It confirms the importance of prevention and
management of such modifiable risk factors at a population
level to bring about reductions in IHD incidence and mortality in
the community. Furthermore, given the potential medication-
stratified differences in risk attributable to lifestyle factors
identified in this study, further investigation of possible
interactive effects may be warranted.
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